<DOC>
	<DOC>NCT00687817</DOC>
	<brief_summary>The primary objective of this study is to determine the overall response rate (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally advanced or metastatic non-small cell lung cancer.</brief_summary>
	<brief_title>Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Key Adults over age 18 years of age with a life expectancy of at least 3 months Histologically or cytologically confirmed nonsmall cell lung cancer at stage IIIB (with pleural effusion), stage IV, or recurrence Measurable disease on cross sectional imaging at least 2 cm in longest diameter (1 cm if measured by spiral CT) Adequate hematologic (ANC ≥ 1500 cells/µL; Hemoglobin ≥9 g/dL; platelets ≥100,000/µL and ≤500,000/µL ), renal (serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min), and hepatic function (bilirubin ≤ 1.5 x ULN, ALT ≤ 3 x ULN, AST ≤ 3 x ULN) Ddimer ≤ 2 x ULN Key Small cell or mixed histology Known history of bleeding diathesis or coagulopathy Any current evidence of clinically significant bleeding defined as gross hematuria, hemoptysis, or GI bleeding Any history of thromboembolic events (e.g., deep vein thrombosis or pulmonary thromboembolism) Prior chemotherapy, immunotherapy or radiotherapy to an area of measurable disease unless disease had recurred after radiotherapy Radiotherapy within 2 weeks preceding Study Day 1 Symptomatic or clinically active CNS disease or metastatic lesions Major surgery within 4 weeks of Study Day 1 Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease) Any history of angina pectoris, coronary artery disease or cerebrovascular accident, or transient ischemic attack A history of any condition requiring antiplatelet therapy with the exception of general cardiovascular prophylaxis with aspirin. Antiplatelet agents are prohibited during the study. Requirement for chronic daily treatment with NSAIDs, antiplatelet drugs, or steroids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>NSCLC</keyword>
</DOC>